Blastic Plasmacytoid Dendritic Cell Neoplasm - Pipeline Insight, 2021

June 2021 | 60 pages | ID: B7FDFEE7A399EN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight’s, “Blastic Plasmacytoid Dendritic Cell Neoplasm - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Blastic Plasmacytoid Dendritic Cell Neoplasm pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Blastic Plasmacytoid Dendritic Cell Neoplasm Understanding

Blastic Plasmacytoid Dendritic Cell Neoplasm: Overview

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) was previously known as natural killer (NK) cell leukemia/lymphoma. As understanding of the biology and origin of this malignancy has improved, the World Health Organization (WHO) established the term blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 2008. BPDCN is currently listed as its own category in the 2016 World Health Organization revision. Most often, BPDCN presents with features of both lymphoma and leukemia. There are little data about BPDCN and there is no established treatment. The average age at diagnosis is 60 to 70 years. There are more men than women who are diagnosed with BPDCN.

'Blastic Plasmacytoid Dendritic Cell Neoplasm - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Blastic Plasmacytoid Dendritic Cell Neoplasm pipeline landscape is provided which includes the disease overview and Blastic Plasmacytoid Dendritic Cell Neoplasm treatment guidelines. The assessment part of the report embraces, in depth Blastic Plasmacytoid Dendritic Cell Neoplasm commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Blastic Plasmacytoid Dendritic Cell Neoplasm collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Blastic Plasmacytoid Dendritic Cell Neoplasm R&D. The therapies under development are focused on novel approaches to treat/improve Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blastic Plasmacytoid Dendritic Cell Neoplasm Emerging Drugs Chapters

This segment of the Blastic Plasmacytoid Dendritic Cell Neoplasm report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Blastic Plasmacytoid Dendritic Cell Neoplasm Emerging Drugs

• IMGN632: ImmunoGen

IMGN632 is a CD123-targeting ADC in clinical development for hematological malignancies including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL). IMGN632 uses one of ImmunoGen’s (the “Company”) novel indolinobenzodiazepine (IGN) payloads, which alkylate DNA without crosslinking. IGNs have been designed to have high potency against tumor cells, while demonstrating less toxicity to normal marrow progenitors than other DNA-targeting payloads. The European Medicines Agency (EMA) granted orphan drug designation to IMGN632 for the treatment of BPDCN in June 2020; IMGN632 also holds this designation in the US. In October 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory BPDCN.

• MB 102: Mustang Bio

MB-102 is a CAR T cell therapy that is produced by engineering patient T cells to recognize and eliminate CD123-expressing tumors. CD123 is widely expressed on bone marrow cells of patients with myelodysplastic syndromes, as well as in hematologic malignancies, including AML, and BPDCN.

Further product details are provided in the report..

Blastic Plasmacytoid Dendritic Cell Neoplasm: Therapeutic Assessment

This segment of the report provides insights about the different Blastic Plasmacytoid Dendritic Cell Neoplasm drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Blastic Plasmacytoid Dendritic Cell Neoplasm

There are approx. 4+ key companies which are developing the therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm. The companies which have their Blastic Plasmacytoid Dendritic Cell Neoplasm drug candidates in the most advanced stage, i.e. phase I/II include, ImmunoGen.

• Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Blastic Plasmacytoid Dendritic Cell Neoplasm pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Blastic Plasmacytoid Dendritic Cell Neoplasm: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Blastic Plasmacytoid Dendritic Cell Neoplasm therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Blastic Plasmacytoid Dendritic Cell Neoplasm drugs.

Blastic Plasmacytoid Dendritic Cell Neoplasm Report Insights

• Blastic Plasmacytoid Dendritic Cell Neoplasm Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Blastic Plasmacytoid Dendritic Cell Neoplasm Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Blastic Plasmacytoid Dendritic Cell Neoplasm drugs?
• How many Blastic Plasmacytoid Dendritic Cell Neoplasm drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Blastic Plasmacytoid Dendritic Cell Neoplasm therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Blastic Plasmacytoid Dendritic Cell Neoplasm and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ImmunoGen
• Mustang Bio
• AbbVie
• Cellectis
• Xencor
• HighPass Bio, Inc.
• Cellex

Key Products

• IMGN632
• MB 102
• Venetoclax
• AlloCAR T
• XmAb14045
• HA-1 T TCR T Cell Immunotherapy
• UniCAR02 T CD123

Contents

Introduction
Executive Summary
Blastic Plasmacytoid Dendritic Cell Neoplasm: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Blastic Plasmacytoid Dendritic Cell Neoplasm – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Blastic Plasmacytoid Dendritic Cell Neoplasm companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Blastic Plasmacytoid Dendritic Cell Neoplasm Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Early Stage Products (Phase I)
  Comparative Analysis
IMGN 632: ImmunoGen
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
  Comparative Analysis
AlloCAR T: Cellectis
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Inactive Products
  Comparative Analysis
Blastic Plasmacytoid Dendritic Cell Neoplasm Key Companies
Blastic Plasmacytoid Dendritic Cell Neoplasm Key Products
Blastic Plasmacytoid Dendritic Cell Neoplasm- Unmet Needs
Blastic Plasmacytoid Dendritic Cell Neoplasm- Market Drivers and Barriers
Blastic Plasmacytoid Dendritic Cell Neoplasm- Future Perspectives and Conclusion
Blastic Plasmacytoid Dendritic Cell Neoplasm Analyst Views
Blastic Plasmacytoid Dendritic Cell Neoplasm Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Blastic Plasmacytoid Dendritic Cell Neoplasm
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Blastic Plasmacytoid Dendritic Cell Neoplasm
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products